Guangdong Jiaying Pharmaceutical Co., Ltd. in 2003 In 3 month by the Meizhou Pharmaceutical reform and the establishment, 2007 In 12 on the success of the company shares listed on the Shenzhen Stock Exchange, Stock Name: Jiaying Pharmaceutical, stock code: 002198; total assets 2.45 billion in net assets 2.13 billion, is a proprietary research and development, production and sales of diversified development companies, high-tech enterprises.

Jiaying Pharmaceutical medicine has produced large-scale modern production base, with a total investment 1.8 billion in new R & D production base covers an area of 5.5 square meters, total construction area of 8 square meters, nearly ten thousand tons of traditional Chinese medicine extraction capacity / years. Annual production capacity of nearly 5 billion. Currently has 5 kinds of formulations were 65 kinds of drugs are the main class for the throat, influenza-like, gastrointestinal type, tonic medicine ; a national patent protection, national protection of traditional Chinese medicine, the exclusive production of brand-name products have Houfengsan, double wind throat lozenges, solid balls, fine ginseng; "Jiaying" trademark in Guangdong Province.

Jiaying Pharmaceutical adhere to independent innovation, and with a number of research institutions to establish a long-term relationship, research and development center with advanced equipment. To build a smooth marketing channels, Jiaying carry out a wide range of pharmaceutical marketing strategy based, relying on the advantages of their products cheap, and increase rural market and end-customer to open up in the domestic 30 provinces, cities and districts to establish a distribution agency, 1500 number of sales outlets, and expand the Hong Kong, Macao, Taiwan, Southeast Asia market.

future, Jiaying Pharmaceutical will be high-quality talent, advanced technology, scientific management as the cornerstone of development, adhering to the "edge products as the core, Product profit targets "business philosophy, strong and big main results; the same time, production and management of both operations and capital, through mergers and acquisitions, and other forms of equity holding in a planned, step by step, actively and steadily involved in other areas, creating greater benefit to society, rewards shareholders.
we want to do something - to promote the Chinese pharmaceutical industry, more like a dream - "Health for All, Wanjia Anfu!"